Navigation Links
SemBioSys updates progress on Apo AI(Milano)
Date:12/24/2009

TSX symbol: SBS

CALGARY, Dec. 24 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS) provided an update today on its progress on plant-produced Apo AI(Milano) in light of the Apo AI(Milano) license agreement between Pfizer Inc. and The Medicines Company, of Parsippany, New Jersey.

"The Medicines Company's acquisition of the exclusive rights to Pfizer's Apo AI(Milano) program is a strong endorsement of Apo AI(Milano) and its potential to rapidly reduce atherosclerotic plaque. The asset is now in the hands of pharmaceutical company that will actively develop the compound with access to the financial means to do so," said James Szarko, Chief Executive Officer of SemBioSys. "The Medicines Company, which specializes in acute cardiac care, recognizes the potential benefit and value of Apo AI(Milano) to address one of the most significant areas of unmet clinical need in the cardiovascular market today. While The Medicines Company did not address a manufacturing solution in their disclosure surrounding the transaction, it is clear that the success of this drug candidate will be highly dependent upon manufacturing technology that can provide Apo AI(Milano) at high purity and at a reasonable cost. Although SemBioSys' Apo AI(Milano) product is different and distinct from that in-licenced by The Medicines Company, our proprietary manufacturing technology is perfectly suited to making their in-licenced product as well as the natural forms of Apo AI."

In collaboration with leading cardiologists and cardiovascular researchers, SemBioSys has confirmed the activity of plant-derived Apo AI(Milano) in seven preclinical models. The Company has demonstrated the anti-atherosclerotic effects of Apo AI(Milano) based on cholesterol mobilization from the arterial wall, lipid content of atherosclerotic plaques, and the reduction of overall volume of atherosclerotic plaque after multiple injections. This year, the Company harvested more than 20 tonnes of safflower containing Apo AI(Milano) from outdoor production operations in Chile and the United States which provided surplus material for the manufacturing scale up at its pilot facility. SemBioSys has also completed a pre-IND (Investigational New Drug) meeting during which the U.S. Food and Drug Administration confirmed the development plan presented by SemBioSys to file an IND application and addressed the proposed design of clinical trials for Apo AI(Milano). SemBioSys continues to conduct discussions with potential partners on its proprietary, plant-derived Apo AI(Milano) product.

About SemBioSys

Calgary, Alberta-based SemBioSys is focused on leveraging its unique proprietary platform to manufacture high-value proteins and oils. SemBioSys' seed-based protein production system can provide for its partners product enablement, exceptionally low cost and unprecedented scalability. SemBioSys is applying the platform with high selectivity to products with tremendous clinical promise and value potential. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI(Milano), a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the obtaining of court and other regulatory approvals and consents, any adjustment with respect to the amount of the non-dilutive financing, including the market price of the securities to be received by New SemBioSys, the satisfaction of closing conditions, and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

SOURCE SemBioSys Genetics Inc.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009
2. SemBioSys announces third quarter 2009 financial and operational results
3. SemBioSys provides an update on Botaneco
4. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
5. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
6. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
7. SemBioSys provides update on insulin program
8. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
9. SemBioSys announces senior management changes
10. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
11. SemBioSys begins phase I/II trial of insulin produced in plant seeds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... ... as Vice President of Clinical Operations. She brings years of expertise in establishing ... From her professional foundation as a licensed occupational therapist, through a variety of ...
(Date:5/23/2017)... ... May 23, 2017 , ... Customers ... their control technology again and again. METTLER TOLEDO has released two new videos ... videos illustrate how integration of the ACT350 into Siemens and Allen Bradley PLCs ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... is exhibiting in booth B2 at the Association for Pathology Informatics Annual ... , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata ...
(Date:5/19/2017)... ... May 19, 2017 , ... In response to the strong base of ... Systems, Inc. announces the release of their Gait Trainer 3 with an Integrated Music ... biomedical system to aid in rehabilitating individuals with cerebral palsy, traumatic brain injury, stroke ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics ... ...
(Date:3/16/2017)... - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
Breaking Biology News(10 mins):